Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17376305 | 0.84 | GPR119 (0.33) | KDM4EMAPTTHRBGPR119USP30 | |
| SCHEMBL2260256 | 0.73 | DPP4 (0.35) | GPR119DPP4USP30MEN1KMT2A | |
| SCHEMBL17376242 | 0.72 | PLAT (0.34) | KDM4EMAPTTHRBGPR119PLAT | |
| SCHEMBL1420420 | 0.69 | DPP4 (0.32) | KDM4EMAPTTHRBGPR119DPP4 | |
| SCHEMBL1847232 | 0.68 | KDM4E (0.32) | KDM4EMAPTTHRBGPR119DPP4 | |
| SCHEMBL1849221 | 0.67 | LIPE (0.32) | GPR119DPP4PLAT | |
| SCHEMBL16963473 | 0.67 | NR1H2 (0.59) | KDM4EMAPTTHRBGPR119MEN1 | |
| SCHEMBL16963472 | 0.67 | NR1H2 (0.59) | KDM4EMAPTTHRBGPR119MEN1 | |
| SCHEMBL2590853 | 0.67 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL2392461 | 0.66 | CHRM2 (0.34) | KDM4EMAPTTHRBGPR119DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249093-A1 | Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249093-A1 | Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | MC4R, MC5R, MC3R | KDM4E 314/4885MAPT 1931/4885THRB 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.